- Home
- CNTX vs PYXS Comparison
CNTX vs PYXS Comparison
Compare CNTX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- PYXS
- Stock Information
- Founded
- CNTX 2015
- PYXS 2018
- Country
- CNTX United States
- PYXS United States
- Employees
- CNTX N/A
- PYXS N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- PYXS Health Care
- Exchange
- CNTX Nasdaq
- PYXS Nasdaq
- Market Cap
- CNTX 78.0M
- PYXS 75.0M
- IPO Year
- CNTX 2021
- PYXS 2021
- Fundamental
- Price
- CNTX $0.79
- PYXS $1.23
- Analyst Decision
- CNTX Strong Buy
- PYXS Buy
- Analyst Count
- CNTX 5
- PYXS 4
- Target Price
- CNTX $5.25
- PYXS $8.67
- AVG Volume (30 Days)
- CNTX 145.6K
- PYXS 384.0K
- Earning Date
- CNTX 08-06-2025
- PYXS 08-14-2025
- Dividend Yield
- CNTX N/A
- PYXS N/A
- EPS Growth
- CNTX N/A
- PYXS N/A
- EPS
- CNTX N/A
- PYXS N/A
- Revenue
- CNTX N/A
- PYXS $2,820,000.00
- Revenue This Year
- CNTX N/A
- PYXS N/A
- Revenue Next Year
- CNTX N/A
- PYXS N/A
- P/E Ratio
- CNTX N/A
- PYXS N/A
- Revenue Growth
- CNTX N/A
- PYXS N/A
- 52 Week Low
- CNTX $0.49
- PYXS $0.83
- 52 Week High
- CNTX $2.70
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- CNTX 58.08
- PYXS 60.01
- Support Level
- CNTX $0.68
- PYXS $0.97
- Resistance Level
- CNTX $0.73
- PYXS $1.38
- Average True Range (ATR)
- CNTX 0.05
- PYXS 0.07
- MACD
- CNTX -0.00
- PYXS 0.01
- Stochastic Oscillator
- CNTX 55.65
- PYXS 92.86
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.